TY  - JOUR 
AU  - Isla, D.
AU  - Sánchez, A.
AU  - Casal Rubio, Joaquín
AU  - Cobo, M.
AU  - Majem, M.
AU  - Reguart, N.
AU  - Zugazagoitia, J.
AU  - Bernabé, R.
PY  - 2023
SN  - 2077-0383
UR  - http://hdl.handle.net/20.500.11940/21741
AB  - Introduction: There are currently three first-line immunotherapy options used as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand 1 (PD-L1) expression (?50%). This manuscript aims to evaluate the...
LA  - eng
TI  - PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
DO  - 10.3390/jcm12155063
T2  - Journal of Clinical Medicine
KW  - AS Vigo
KW  - CHUVI
VL  - 12
ER  -